Briefs: Dr. Agarwal's Eye Hospital and Apitoria Pharma
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Subscribe To Our Newsletter & Stay Updated